Aura Biosciences Inc (AURA) - Net Assets
Based on the latest financial reports, Aura Biosciences Inc (AURA) has net assets worth $107.25 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($137.68 Million) and total liabilities ($30.43 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Aura Biosciences Inc (AURA) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $107.25 Million |
| % of Total Assets | 77.9% |
| Annual Growth Rate | 28.25% |
| 5-Year Change | -10.11% |
| 10-Year Change | N/A |
| Growth Volatility | 259.63 |
Aura Biosciences Inc - Net Assets Trend (2019–2025)
This chart illustrates how Aura Biosciences Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see AURA stock market capitalisation.
Annual Net Assets for Aura Biosciences Inc (2019–2025)
The table below shows the annual net assets of Aura Biosciences Inc from 2019 to 2025. Also explore AURA net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $136.91 Million | -9.91% |
| 2024-12-31 | $151.97 Million | -32.71% |
| 2023-12-31 | $225.85 Million | +15.47% |
| 2022-12-31 | $195.58 Million | +28.41% |
| 2021-12-31 | $152.31 Million | +686.63% |
| 2020-12-31 | $19.36 Million | -37.06% |
| 2019-12-31 | $30.76 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aura Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 38573800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $-102.00K | -0.07% |
| Other Components | $617.43 Million | 450.97% |
| Total Equity | $136.91 Million | 100.00% |
Aura Biosciences Inc Competitors by Market Cap
The table below lists competitors of Aura Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Neogen Chemicals Limited
NSE:NEOGEN
|
$684.13 Million |
|
Latitude Group Holdings Ltd
AU:LFS
|
$684.18 Million |
|
Teyi Pharmaceutical Group Co Ltd
SHE:002728
|
$684.28 Million |
|
Anhui Korrun Co Ltd
SHE:300577
|
$684.36 Million |
|
REVO INSURANCE SPA O.N.
F:H0O
|
$683.94 Million |
|
Once Upon a Farm, PBC
NYSE:OFRM
|
$683.92 Million |
|
Hubei Biocause Heilen Pharmaceutical Co. Ltd.
SHE:301211
|
$683.80 Million |
|
Community West Bancshares
NASDAQ:CWBC
|
$683.78 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aura Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 151,970,000 to 136,913,000, a change of -15,057,000 (-9.9%).
- Net loss of 106,191,000 reduced equity.
- New share issuances of 52,571,000 increased equity.
- Other comprehensive income decreased equity by 365,000.
- Other factors increased equity by 38,928,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-106.19 Million | -77.56% |
| Share Issuances | $52.57 Million | +38.4% |
| Other Comprehensive Income | $-365.00K | -0.27% |
| Other Changes | $38.93 Million | +28.43% |
| Total Change | $- | -9.91% |
Book Value vs Market Value Analysis
This analysis compares Aura Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 657.28x to 3.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.01 | $6.92 | x |
| 2020-12-31 | $0.66 | $6.92 | x |
| 2021-12-31 | $5.21 | $6.92 | x |
| 2022-12-31 | $6.53 | $6.92 | x |
| 2023-12-31 | $5.70 | $6.92 | x |
| 2024-12-31 | $3.06 | $6.92 | x |
| 2025-12-31 | $2.27 | $6.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aura Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -77.56%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-77.56%) is below the historical average (-59.30%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -78.67% | 0.00% | 0.00x | 1.20x | $-27.28 Million |
| 2020 | -114.68% | 0.00% | 0.00x | 1.14x | $-24.14 Million |
| 2021 | -23.14% | 0.00% | 0.00x | 1.05x | $-50.48 Million |
| 2022 | -30.05% | 0.00% | 0.00x | 1.14x | $-78.32 Million |
| 2023 | -33.83% | 0.00% | 0.00x | 1.13x | $-98.99 Million |
| 2024 | -57.19% | 0.00% | 0.00x | 1.20x | $-102.12 Million |
| 2025 | -77.56% | 0.00% | 0.00x | 1.24x | $-119.88 Million |
Industry Comparison
This section compares Aura Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $161,895,707
- Average return on equity (ROE) among peers: -42.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aura Biosciences Inc (AURA) | $107.25 Million | -78.67% | 0.28x | $683.95 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $109.30 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $170.10 Million | -16.06% | 0.05x | $310.51 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-11.42 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-12.35 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.35 Billion |
| Arbutus Biopharma Corp (ABUS) | $38.29 Million | -30.60% | 0.11x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.66 Million | -45.66% | 0.56x | $9.31 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $199.76 Million | -82.32% | 0.11x | $4.61 Billion |
About Aura Biosciences Inc
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the … Read more